NM_003560.4:c.238G>A

Variant summary

Our verdict is Pathogenic. The variant received 16 ACMG points: 16P and 0B. PM2PM5PP3_StrongPP5_Very_Strong

The NM_003560.4(PLA2G6):​c.238G>A​(p.Ala80Thr) variant causes a missense change. The variant allele was found at a frequency of 0.00000372 in 1,613,066 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Likely pathogenic (★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. A80S) has been classified as Likely pathogenic.

Frequency

Genomes: 𝑓 0.000013 ( 0 hom., cov: 30)
Exomes 𝑓: 0.0000027 ( 0 hom. )

Consequence

PLA2G6
NM_003560.4 missense

Scores

3
12
4

Clinical Significance

Pathogenic/Likely pathogenic criteria provided, multiple submitters, no conflicts P:7

Conservation

PhyloP100: 6.42

Publications

17 publications found
Variant links:
Genes affected
PLA2G6 (HGNC:9039): (phospholipase A2 group VI) The protein encoded by this gene is an A2 phospholipase, a class of enzyme that catalyzes the release of fatty acids from phospholipids. The encoded protein may play a role in phospholipid remodelling, arachidonic acid release, leukotriene and prostaglandin synthesis, fas-mediated apoptosis, and transmembrane ion flux in glucose-stimulated B-cells. Several transcript variants encoding multiple isoforms have been described, but the full-length nature of only three of them have been determined to date. [provided by RefSeq, Dec 2010]
PLA2G6 Gene-Disease associations (from GenCC):
  • neurodegeneration with brain iron accumulation 2A
    Inheritance: AR Classification: DEFINITIVE, STRONG, SUPPORTIVE Submitted by: G2P, Ambry Genetics, Genomics England PanelApp, Orphanet, Labcorp Genetics (formerly Invitae)
  • neurodegeneration with brain iron accumulation 2B
    Inheritance: AR Classification: DEFINITIVE, STRONG Submitted by: Ambry Genetics, Genomics England PanelApp, Labcorp Genetics (formerly Invitae)
  • PLA2G6-associated neurodegeneration
    Inheritance: AR Classification: DEFINITIVE Submitted by: ClinGen
  • autosomal recessive Parkinson disease 14
    Inheritance: AR Classification: STRONG, MODERATE, SUPPORTIVE Submitted by: Ambry Genetics, Labcorp Genetics (formerly Invitae), Genomics England PanelApp, Orphanet

Genome browser will be placed here

ACMG classification

Classification was made for transcript

Our verdict: Pathogenic. The variant received 16 ACMG points.

PM2
Very rare variant in population databases, with high coverage;
PM5
Other missense variant is known to change same aminoacid residue: Variant chr22-38145625-C-A is described in ClinVar as Conflicting_classifications_of_pathogenicity. ClinVar VariationId is 1474450.
PP3
MetaRNN computational evidence supports a deleterious effect, 0.981
PP5
Variant 22-38145625-C-T is Pathogenic according to our data. Variant chr22-38145625-C-T is described in ClinVar as Pathogenic/Likely_pathogenic. ClinVar VariationId is 6202.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect Exon rank MANE Protein UniProt
PLA2G6NM_003560.4 linkc.238G>A p.Ala80Thr missense_variant Exon 3 of 17 ENST00000332509.8 NP_003551.2 O60733-1

Ensembl

Gene Transcript HGVSc HGVSp Effect Exon rank TSL MANE Protein Appris UniProt
PLA2G6ENST00000332509.8 linkc.238G>A p.Ala80Thr missense_variant Exon 3 of 17 1 NM_003560.4 ENSP00000333142.3 O60733-1

Frequencies

GnomAD3 genomes
AF:
0.0000132
AC:
2
AN:
152028
Hom.:
0
Cov.:
30
show subpopulations
Gnomad AFR
AF:
0.00
Gnomad AMI
AF:
0.00
Gnomad AMR
AF:
0.0000656
Gnomad ASJ
AF:
0.00
Gnomad EAS
AF:
0.000193
Gnomad SAS
AF:
0.00
Gnomad FIN
AF:
0.00
Gnomad MID
AF:
0.00
Gnomad NFE
AF:
0.00
Gnomad OTH
AF:
0.00
GnomAD2 exomes
AF:
0.00000803
AC:
2
AN:
249158
AF XY:
0.0000149
show subpopulations
Gnomad AFR exome
AF:
0.00
Gnomad AMR exome
AF:
0.00
Gnomad ASJ exome
AF:
0.00
Gnomad EAS exome
AF:
0.0000547
Gnomad FIN exome
AF:
0.00
Gnomad NFE exome
AF:
0.00000888
Gnomad OTH exome
AF:
0.00
GnomAD4 exome
AF:
0.00000274
AC:
4
AN:
1460920
Hom.:
0
Cov.:
32
AF XY:
0.00000275
AC XY:
2
AN XY:
726662
show subpopulations
African (AFR)
AF:
0.00
AC:
0
AN:
33464
American (AMR)
AF:
0.00
AC:
0
AN:
44596
Ashkenazi Jewish (ASJ)
AF:
0.00
AC:
0
AN:
26102
East Asian (EAS)
AF:
0.00
AC:
0
AN:
39674
South Asian (SAS)
AF:
0.00
AC:
0
AN:
86012
European-Finnish (FIN)
AF:
0.00
AC:
0
AN:
53356
Middle Eastern (MID)
AF:
0.00
AC:
0
AN:
5760
European-Non Finnish (NFE)
AF:
0.00000360
AC:
4
AN:
1111598
Other (OTH)
AF:
0.00
AC:
0
AN:
60358
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.475
Heterozygous variant carriers
0
1
1
2
2
3
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Exome Het
Variant carriers
0
2
4
6
8
10
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
GnomAD4 genome
AF:
0.0000131
AC:
2
AN:
152146
Hom.:
0
Cov.:
30
AF XY:
0.0000134
AC XY:
1
AN XY:
74384
show subpopulations
African (AFR)
AF:
0.00
AC:
0
AN:
41508
American (AMR)
AF:
0.0000655
AC:
1
AN:
15274
Ashkenazi Jewish (ASJ)
AF:
0.00
AC:
0
AN:
3470
East Asian (EAS)
AF:
0.000193
AC:
1
AN:
5168
South Asian (SAS)
AF:
0.00
AC:
0
AN:
4828
European-Finnish (FIN)
AF:
0.00
AC:
0
AN:
10584
Middle Eastern (MID)
AF:
0.00
AC:
0
AN:
294
European-Non Finnish (NFE)
AF:
0.00
AC:
0
AN:
67998
Other (OTH)
AF:
0.00
AC:
0
AN:
2112
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.550
Heterozygous variant carriers
0
0
1
1
2
2
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance
Alfa
AF:
0.000160
Hom.:
0
Bravo
AF:
0.00000756
ExAC
AF:
0.00000824
AC:
1
Asia WGS
AF:
0.000289
AC:
1
AN:
3478

ClinVar

Significance: Pathogenic/Likely pathogenic
Submissions summary: Pathogenic:7
Revision: criteria provided, multiple submitters, no conflicts
LINK: link

Submissions by phenotype

Infantile neuroaxonal dystrophy;C1857747:Neurodegeneration with brain iron accumulation 2B;C2751842:Autosomal recessive Parkinson disease 14 Pathogenic:3
-
Juno Genomics, Hangzhou Juno Genomics, Inc
Significance:Pathogenic
Review Status:criteria provided, single submitter
Collection Method:clinical testing

PM2_Supporting+PM3_VeryStrong+PP1_Strong+PP4 -

Jun 24, 2024
Fulgent Genetics, Fulgent Genetics
Significance:Pathogenic
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

May 30, 2023
Mayo Clinic Laboratories, Mayo Clinic
Significance:Pathogenic
Review Status:criteria provided, single submitter
Collection Method:clinical testing

PM3_Strong, PS3_Moderate, PP1_Moderate, PM2 -

Infantile neuroaxonal dystrophy Pathogenic:1
Aug 08, 2024
Labcorp Genetics (formerly Invitae), Labcorp
Significance:Pathogenic
Review Status:criteria provided, single submitter
Collection Method:clinical testing

This sequence change replaces alanine, which is neutral and non-polar, with threonine, which is neutral and polar, at codon 80 of the PLA2G6 protein (p.Ala80Thr). This variant is present in population databases (rs121908685, gnomAD 0.006%). This missense change has been observed in individuals with clinical features of PLA2G6-related conditions (PMID: 16783378, 22934738, 30772976, 34622992). It has also been observed to segregate with disease in related individuals. ClinVar contains an entry for this variant (Variation ID: 6202). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt PLA2G6 protein function with a positive predictive value of 80%. Experimental studies have shown that this missense change does not substantially affect PLA2G6 function (PMID: 26755131). For these reasons, this variant has been classified as Pathogenic. -

not provided Pathogenic:1
Oct 31, 2022
GeneDx
Significance:Pathogenic
Review Status:criteria provided, single submitter
Collection Method:clinical testing

Published functional studies demonstrate a damaging effect, as A80T fails to restore wild type protein function and results in significant deficits in neurological function in flies (Mori et al., 2019); Not observed at a significant frequency in large population cohorts (gnomAD); In silico analysis supports a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 22934738, 30772976, 18799783, 19138334, 16783378, 26755131, 34622992, 35911906, 27196560, 31548400) -

PLA2G6-associated neurodegeneration Pathogenic:1
Jan 24, 2023
Broad Center for Mendelian Genomics, Broad Institute of MIT and Harvard
Significance:Likely pathogenic
Review Status:criteria provided, single submitter
Collection Method:curation

The p.Ala80Thr variant in PLA2G6 has been reported in 5 individuals with PLA2G6-associated neurodegeneration (PMID: 16783378, 19138334, 27196560, 30772976, 34622992), segregated with disease in 2 individuals from 1 family (PMID: 30772976), and has been identified in 0.005% (1/18286) of East Asian chromosomes by the Genome Aggregation Database (gnomAD, http://gnomad.broadinstitute.org; dbSNP ID: rs121908685). Although this variant has been seen in the general population in a heterozygous state, its frequency is low enough to be consistent with a recessive carrier frequency. This variant has also been reported in ClinVar (Variation ID#: 6202) and has been interpreted as pathogenic by GeneDx and OMIM and as a variant of uncertain significance by Mayo Clinic Laboratories (Mayo Clinic) and Invitae. Of the 5 affected individuals, 1 of those was a homozygote, and 1 was a compound heterozygote that carried a reported pathogenic variant in trans, which increases the likelihood that the p.Ala80Thr variant is pathogenic (VariationID: 30371; PMID: 27196560, 30772976). In vitro functional studies provide some evidence that the p.Ala80Thr variant may slightly impact protein function (PMID: 31548400). However, these types of assays may not accurately represent biological function. Computational prediction tools and conservation analyses do not provide strong support for or against an impact to the protein. In summary, although additional studies are required to fully establish its clinical significance, this variant is likely pathogenic for autosomal recessive PLA2G6-associated neurodegeneration. ACMG/AMP Criteria applied: PM2_supporting, PP1, PM3_strong, PS3_supporting (Richards 2015). -

Neurodegeneration with brain iron accumulation 2B Pathogenic:1
Oct 28, 2008
OMIM
Significance:Pathogenic
Review Status:no assertion criteria provided
Collection Method:literature only

- -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
AlphaMissense
Uncertain
0.54
BayesDel_addAF
Pathogenic
0.26
D
BayesDel_noAF
Pathogenic
0.30
CADD
Uncertain
24
DANN
Uncertain
1.0
DEOGEN2
Benign
0.30
T;.;.;.
Eigen
Uncertain
0.43
Eigen_PC
Uncertain
0.42
FATHMM_MKL
Uncertain
0.97
D
LIST_S2
Uncertain
0.94
D;D;.;D
M_CAP
Uncertain
0.13
D
MetaRNN
Pathogenic
0.98
D;D;D;D
MetaSVM
Uncertain
-0.27
T
MutationAssessor
Uncertain
2.6
M;M;M;.
PhyloP100
6.4
PrimateAI
Uncertain
0.53
T
PROVEAN
Uncertain
-2.6
D;N;N;D
REVEL
Uncertain
0.44
Sift
Benign
0.069
T;T;T;D
Sift4G
Benign
0.086
T;T;T;D
Polyphen
0.85
P;D;D;.
Vest4
0.73
MutPred
0.89
Loss of stability (P = 0.1277);Loss of stability (P = 0.1277);Loss of stability (P = 0.1277);Loss of stability (P = 0.1277);
MVP
0.87
MPC
0.87
ClinPred
0.94
D
GERP RS
5.3
Varity_R
0.25
gMVP
0.74
Mutation Taster
=0/100
disease causing

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.030
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

Other links and lift over

dbSNP: rs121908685; hg19: chr22-38541632; API